Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK3 | P52333 | 15/20 | 0.56 |
| ▸ | IRAK4 | Q9NWZ3 | 6/20 | 0.56 |
| ▸ | STAT6 | P42226 | 4/20 | 0.46 |
| ▸ | JAK2 | O60674 | 5/20 | 0.45 |
| ▸ | JAK1 | P23458 | 5/20 | 0.45 |
| ▸ | TYK2 | P29597 | 3/20 | 0.45 |
| ▸ | CSF1R | P07333 | 1/20 | 0.40 |
| ▸ | BTK | Q06187 | 1/20 | 0.40 |
| ▸ | STAT3 | P40763 | 1/20 | 0.38 |
| ▸ | SYK | P43405 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2474857 | 1.00 | JAK3 (0.56) | JAK3IRAK4STAT6JAK2JAK1 | |
| SCHEMBL2479583 | 0.91 | JAK3 (0.58) | JAK3IRAK4STAT6JAK2JAK1 | |
| SCHEMBL2479578 | 0.91 | JAK3 (0.58) | JAK3IRAK4STAT6JAK2JAK1 | |
| SCHEMBL15355506 | 0.88 | JAK3 (0.52) | JAK3IRAK4STAT6JAK2JAK1 | |
| SCHEMBL2504218 | 0.88 | JAK3 (0.52) | JAK3IRAK4STAT6JAK2JAK1 | |
| SCHEMBL2475503 | 0.83 | STAT6 (0.55) | JAK3IRAK4STAT6JAK2JAK1 | |
| SCHEMBL2475499 | 0.83 | STAT6 (0.55) | JAK3IRAK4STAT6JAK2JAK1 | |
| SCHEMBL2510104 | 0.81 | STAT6 (0.53) | JAK3IRAK4STAT6JAK2JAK1 | |
| SCHEMBL13337355 | 0.80 | JAK3 (0.41) | JAK3IRAK4STAT6JAK2JAK1 | |
| SCHEMBL2483961 | 0.79 | STAT6 (0.56) | JAK3IRAK4STAT6JAK2JAK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2380877-A1 | PYRIDINE-3-CARBOXYAMIDE DERIVATIVE | Kowa Company, Ltd. (JP) | 2011-10-26 | — | — | EP | claimed |
| US-20110237590-A1 | PYRIDINE-3-CARBOXYAMIDE DERIVATIVE | KOWA COMPANY, LTD. (JP) | 2011-09-29 | — | — | US | claimed |
| US-8575153-B2 | Pyridine-3-carboxyamide derivative | KOWA COMPANY, LTD. (JP) | 2013-11-05 | — | — | US | disclosed |
| EP-2380877-A1 | PYRIDINE-3-CARBOXYAMIDE DERIVATIVE | Kowa Company, Ltd. (JP) | 2011-10-26 | — | — | EP | disclosed |
| US-20110237590-A1 | PYRIDINE-3-CARBOXYAMIDE DERIVATIVE | KOWA COMPANY, LTD. (JP) | 2011-09-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110237590-A1 | PYRIDINE-3-CARBOXYAMIDE DERIVATIVE | JAK3, JAK1, UACA | JAK3 1/4885IRAK4 128/4885STAT6 8/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.